Aclaris Therapeutics Croissance future
Future contrôle des critères 1/6
Les bénéfices de Aclaris Therapeutics devraient diminuer de 4.4% par an tandis que son chiffre d'affaires annuel devrait croître de 13% par an. Le BPA devrait croître de en hausse de 2.5% par an.
Informations clés
-4.4%
Taux de croissance des bénéfices
2.5%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 23.8% |
| Taux de croissance des recettes | 13.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 18 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 12
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -56 | -57 | -46 | 5 |
| 12/31/2025 | 12 | -43 | -43 | -30 | 8 |
| 12/31/2024 | 16 | -42 | -17 | 15 | 7 |
| 9/30/2024 | 27 | -37 | -18 | -18 | N/A |
| 6/30/2024 | 32 | -59 | -65 | -64 | N/A |
| 3/31/2024 | 31 | -77 | -74 | -73 | N/A |
| 12/31/2023 | 31 | -88 | -80 | -78 | N/A |
| 9/30/2023 | 21 | -115 | -92 | -91 | N/A |
| 6/30/2023 | 31 | -105 | -75 | -74 | N/A |
| 3/31/2023 | 31 | -96 | -74 | -73 | N/A |
| 12/31/2022 | 30 | -87 | -68 | -68 | N/A |
| 9/30/2022 | 24 | -82 | -66 | -66 | N/A |
| 6/30/2022 | 6 | -83 | -69 | -68 | N/A |
| 3/31/2022 | 6 | -81 | -61 | -61 | N/A |
| 12/31/2021 | 7 | -91 | -52 | -52 | N/A |
| 9/30/2021 | 7 | -82 | -44 | -44 | N/A |
| 6/30/2021 | 7 | -71 | -46 | -45 | N/A |
| 3/31/2021 | 7 | -65 | -44 | -44 | N/A |
| 12/31/2020 | 6 | -51 | -39 | -39 | N/A |
| 9/30/2020 | 6 | -57 | -51 | -50 | N/A |
| 6/30/2020 | 6 | -69 | -63 | -61 | N/A |
| 3/31/2020 | 4 | -102 | -73 | -72 | N/A |
| 12/31/2019 | 4 | -114 | -98 | -96 | N/A |
| 9/30/2019 | 5 | -118 | -105 | -103 | N/A |
| 6/30/2019 | 5 | -115 | -111 | -110 | N/A |
| 3/31/2019 | 6 | -79 | -112 | -110 | N/A |
| 12/31/2018 | 6 | -82 | -102 | -101 | N/A |
| 9/30/2018 | 5 | -81 | -94 | -92 | N/A |
| 6/30/2018 | 5 | -79 | N/A | -76 | N/A |
| 3/31/2018 | 3 | -86 | N/A | -64 | N/A |
| 12/31/2017 | 2 | -50 | N/A | -55 | N/A |
| 9/30/2017 | 1 | -57 | N/A | -45 | N/A |
| 6/30/2017 | N/A | -50 | N/A | -41 | N/A |
| 3/31/2017 | N/A | -48 | N/A | -40 | N/A |
| 12/31/2016 | N/A | -48 | N/A | -35 | N/A |
| 9/30/2016 | N/A | -42 | N/A | -31 | N/A |
| 6/30/2016 | N/A | -42 | N/A | -31 | N/A |
| 3/31/2016 | N/A | -33 | N/A | -24 | N/A |
| 12/31/2015 | N/A | -23 | N/A | -20 | N/A |
| 9/30/2015 | N/A | -21 | N/A | -19 | N/A |
| 6/30/2015 | N/A | -13 | N/A | -10 | N/A |
| 3/31/2015 | N/A | -12 | N/A | -9 | N/A |
| 12/31/2014 | N/A | -11 | N/A | -8 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ACRS devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ACRS devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ACRS devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ACRS ( 13% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ACRS ( 13% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ACRS devrait être élevé dans 3 ans